Preclinical Study for Canine Malignant Melanoma and Other Solid Tumor Types
Craig A Clifford DVM, MS, DACVIM (Oncology), Kristen Kicenuik, DVM, DACVIM (Oncology), Christine Mullin, VMD, Diplomate ACVIM (Oncology), and Rebecca Risbon, VMD, DACVIM (Oncology)
Hope Veterinary Specialists is seeking patients for a preclinical study for dogs with any form of malignant melanoma (oral, digit, cutaneous/dermal) as well as other solid tumor types in or under the skin. We are collaborating with MBF Therapeutics, a research group that is developing novel cancer vaccines to target melanoma and other important canine cancers.
The objective of this investigation is to identify specific anti-cancer immune system cells in the peripheral blood and to correlate the findings with cancer cell proteins present in excised tumor tissue. The purpose, therefore, is to provide supportive information that the vaccines in development are properly designed to deliver an effective, well-targeted immune system attack against the cancer cells, with the ultimate hope of providing new and novel therapies, thus resulting in a better clinical outcome.
This investigation is above and beyond the diagnostic and treatment objectives of your dog’s veterinary oncologist/surgeon. It is also important to note that this investigation does not include the administration of a cancer vaccine. This study simply utilizes a portion of the cancer tissue that is already being removed and submitted for biopsy. Dogs can then go on to receive standard of care therapy as directed by the oncology team at HopeVS.
Inclusion Criteria/Exclusion Criteria
- Confirmed or highly suspected diagnosis of malignant melanoma (oral, digit, cutaneous/dermal) or other solid tumor types in or under the skin
- Must not have had cancer therapy for the tumor in question
- Tumor is to be surgically removed at HopeVS
- Owner permission must be given for a small sample of tumor and tube of peripheral blood to be taken and submitted for analysis
- Informed consent form must be signed by the owner
There is a small financial incentive provided to owners who enroll their dog in this preclinical study.
For more information, please contact us:
P: (610) 296-2099